Recent Advances, Approaches and Challenges in Targeting Pathways for Potential COVID-19 Vaccines Development

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2020 Oct 2

PMID 33006053

Citations 30

Authors

Daniela Calina

Chandan Sarkar

Andreea Letitia Arsene

Bahare Salehi

Anca Oana Docea

Milon Mondal

Muhammad Torequl Islam

Alireza Zali

Javad Sharifi-Rad

Affiliations

Soon will be listed here.

Abstract

During the COVID-19 pandemic in a modern era, there is a global consensus on the need for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable control. Developing these vaccines is fundamental to public health. This urgent need is supported by the scientific explosion in structural and genomic biology that facilitates the urgent development of an ideal COVID-19 vaccine, using new pathways to facilitate its large-scale development, testing, and manufacture. Here, we summarize the types of COVID-19 candidate vaccines, their current stage in early testing in human clinical trials, and the challenges for their implementation.

Citing Articles

FOXA2 attenuates lipopolysaccharide‑induced pneumonia by inhibiting the inflammatory response, oxidative stress and apoptosis through blocking of p38/STAT3 signaling.

Xue Z, Li Y, Xiao S, Zhang H, Xu J Exp Ther Med. 2023; 26(4):469.

PMID: 37664675 PMC: 10469380. DOI: 10.3892/etm.2023.12168.

Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models.

Park S, Jang M, Lim K, Seo J, Im W, Han K Arch Toxicol. 2023; 97(9):2429-2440.

PMID: 37491472 DOI: 10.1007/s00204-023-03549-6.

Development of SARS-CoV-2 Vaccine: Challenges and Prospects.

Mahboob T, Ismail A, Raza Shah M, Rahmatullah M, Paul A, Pereira M Diseases. 2023; 11(2).

PMID: 37092446 PMC: 10123684. DOI: 10.3390/diseases11020064.

COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies.

Polatoglu I, Oncu-Oner T, Dalman I, Ozdogan S MedComm (2020). 2023; 4(2):e228.

PMID: 37041762 PMC: 10082934. DOI: 10.1002/mco2.228.

Dynamic changes in radiological parameters, immune cells, selected miRNAs, and cytokine levels in peripheral blood of patients with severe COVID‑19.

Bukreieva T, Kyryk V, Nikulina V, Svitina H, Vega A, Chybisov O Biomed Rep. 2023; 18(5):33.

PMID: 37034572 PMC: 10074022. DOI: 10.3892/br.2023.1615.

References

Haralambieva I, Ovsyannikova I, Pankratz V, Kennedy R, Jacobson R, Poland G . The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2012; 12(1):57-70. PMC: 3570049. DOI: 10.1586/erv.12.134. View

Alshukairi A, Khalid I, Ahmed W, Dada A, Bayumi D, Malic L . Antibody Response and Disease Severity in Healthcare Worker MERS Survivors. Emerg Infect Dis. 2016; 22(6). PMC: 4880093. DOI: 10.3201/eid2206.160010. View

Wang C, Li W, Drabek D, Okba N, van Haperen R, Osterhaus A . A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11(1):2251. PMC: 7198537. DOI: 10.1038/s41467-020-16256-y. View

Beavis K, Matushek S, Abeleda A, Bethel C, Hunt C, Gillen S . Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J Clin Virol. 2020; 129:104468. PMC: 7255182. DOI: 10.1016/j.jcv.2020.104468. View

Tetro J . Is COVID-19 receiving ADE from other coronaviruses?. Microbes Infect. 2020; 22(2):72-73. PMC: 7102551. DOI: 10.1016/j.micinf.2020.02.006. View

Jiang S, Hillyer C, Du L . Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020; 41(5):355-359. PMC: 7129017. DOI: 10.1016/j.it.2020.03.007. View

Powlson J, Wright D, Zeltina A, Giza M, Nielsen M, Rampling T . Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. Cell Rep. 2019; 29(9):2537-2545.e3. PMC: 6899439. DOI: 10.1016/j.celrep.2019.10.105. View

Petricciani J, Sheets R, Griffiths E, Knezevic I . Adventitious agents in viral vaccines: lessons learned from 4 case studies. Biologicals. 2014; 42(5):223-36. DOI: 10.1016/j.biologicals.2014.07.003. View

Cao W, Liu W, Zhang P, Zhang F, Richardus J . Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007; 357(11):1162-3. DOI: 10.1056/NEJMc070348. View

10.

Kissler S, Tedijanto C, Goldstein E, Grad Y, Lipsitch M . Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020; 368(6493):860-868. PMC: 7164482. DOI: 10.1126/science.abb5793. View

11.

Goumenou M, Sarigiannis D, Tsatsakis A, Anesti O, Docea A, Petrakis D . COVID‑19 in Northern Italy: An integrative overview of factors possibly influencing the sharp increase of the outbreak (Review). Mol Med Rep. 2020; 22(1):20-32. PMC: 7248465. DOI: 10.3892/mmr.2020.11079. View

12.

Rauch S, Jasny E, Schmidt K, Petsch B . New Vaccine Technologies to Combat Outbreak Situations. Front Immunol. 2018; 9:1963. PMC: 6156540. DOI: 10.3389/fimmu.2018.01963. View

13.

Yang L, Tian D, Liu W . [Strategies for vaccine development of COVID-19]. Sheng Wu Gong Cheng Xue Bao. 2020; 36(4):593-604. DOI: 10.13345/j.cjb.200094. View

14.

Wu L, Wang N, Chang Y, Tian X, Na D, Zhang L . Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2008; 13(10):1562-4. PMC: 2851497. DOI: 10.3201/eid1310.070576. View

15.

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

16.

Marston H, Paules C, Fauci A . The Critical Role of Biomedical Research in Pandemic Preparedness. JAMA. 2017; 318(18):1757-1758. DOI: 10.1001/jama.2017.15033. View

17.

Hsueh P, Huang L, Chen P, Kao C, Yang P . Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004; 10(12):1062-6. PMC: 7129952. DOI: 10.1111/j.1469-0691.2004.01009.x. View

18.

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

19.

Payne D, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M . Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg Infect Dis. 2016; 22(10):1824-6. PMC: 5038413. DOI: 10.3201/eid2210.160706. View

20.

Calina D, Hartung T, Docea A, Spandidos D, Egorov A, Shtilman M . COVID-19 vaccines: ethical framework concerning human challenge studies. Daru. 2020; 28(2):807-812. PMC: 7449865. DOI: 10.1007/s40199-020-00371-8. View